The plane laden with vaccines had just rolled to a stop at Santiago’s airport in late January and Chilean President Sebastian Pinera was beaming. “Today is a day of joy, emotion and hope,” he said.
The source of that hope: China — a country that Chile and dozens of other nations are depending on to help rescue them from the COVID-19 pandemic.
China’s vaccine diplomacy campaign has been a surprising success: It has pledged about 500 million doses of its vaccine to more than 45 countries, according to a country-by-country tally by The Associated Press (AP).
With just four of China’s many vaccine makers able to produce at least 2.6 billion doses this year, a large part of the world’s population would end up inoculated not with the fancy Western vaccines boasting headline-grabbing efficacy rates, but with China’s humble, traditionally made shots.
Amid a dearth of public data on China’s vaccines, fears over their efficacy and safety are still pervasive in the countries depending on them, along with concerns about what China might want in return for deliveries.
Nonetheless, inoculations with Chinese vaccines have begun in more than 25 countries, and the shots have been delivered to another 11, according to the AP’s tally, based on independent reporting in those countries along with government and company announcements.
It is a potential face-saving coup for China, which has been determined to transform itself from an object of mistrust over its initial mishandling of the COVID-19 outbreak to a savior.
“We’re seeing certainly real-time vaccine diplomacy start to play out, with China in the lead in terms of being able to manufacture vaccines within China and make them available to others,” said Krishna Udayakumar, founding director of the Duke Global Health Innovation Center at Duke University.
China has said it is supplying “vaccine aid” to 53 countries and exports to 27, but it rejected a request by the AP for the list.
Beijing has denied vaccine diplomacy, and a Chinese Ministry of Foreign Affairs spokesperson said China considered the vaccine a “global public good.”
Chinese experts reject any connection between the export of its vaccines and the revamping of its image.
China has targeted the low and middle-income countries largely left behind as rich nations scooped up most of the pricey vaccines produced by the likes of Pfizer and Moderna. Despite a few delays of its own, China has largely capitalized on slower-than-hoped-for deliveries by US and European vaccine makers.
Like many other countries, Chile received far fewer doses of the Pfizer vaccine than promised. Chinese company Sinovac acted quickly, sending in 4 million doses.
The choices are limited for Chile and many other low and middle-income countries. Vaccine deployment globally has been dominated by rich nations, which have snapped up 5.4 billion of the 7.8 billion doses purchased worldwide, Duke University said.
China’s vaccines, which can be stored in standard refrigerators, are attractive to many countries that might struggle to accommodate the ultra-cold storage needs of vaccines like Pfizer’s.
Sinovac and Sinopharm rely on a traditional technology in which a live virus is killed and then purified, triggering an immune response.
Some countries view it as safer than the newer, less-proven technology used by some Western competitors that targets the novel coronavirus’ spike protein, despite the lack of publicly available safety data on the Chinese vaccines.
In Europe, China is providing the vaccine to countries such as Serbia and Hungary — a significant geopolitical victory in Central Europe and the Balkans, where the West, China and Russia are competing for political and economic influence. Hungary is the first EU country to use a Chinese vaccine.
However, China’s vaccine diplomacy would be only as good as the vaccines it is offering, and it still faces hurdles.
“The Chinese vaccine, in particular, there was insufficient data available compared to other vaccines,” said Ahmed Hamdan Zayed, a nurse in Egypt who overcame his initial reluctance and received Sinopharm’s vaccine.
Sinopharm, which said its vaccine was 79 percent effective based on interim data from clinical trials, did not respond to interview requests.
Chinese vaccine companies have been “slow and spotty” in releasing their trial data, compared with companies like Pfizer and Moderna, said Yanzhong Huang (黃嚴忠), a global health expert at the US think tank Council for Foreign Relations.
None of China’s three vaccine candidates used globally have publicly released their late-stage clinical trial data.
CanSino, another Chinese company with a one-shot vaccine that it says is 65 percent effective, declined to be interviewed.
There is also confusion around Sinovac’s efficacy. In Turkey, where Sinovac conducted part of its efficacy trials, officials have said the vaccine was 91 percent effective.
However, in Brazil, officials revised the efficacy rate in late-stage clinical trials from 78 percent to just more than 50 percent after including mild infections.
An expert panel in Hong Kong published data submitted by Sinovac to health regulators that showed the vaccine was just more than 50 percent effective.
Globally, public health officials have said any vaccine that is at least 50 percent effective is useful.
Receiving countries are also worried that China’s vaccine diplomacy might come at a cost. In the Philippines, where Beijing is donating 600,000 vaccines, a senior diplomat said Chinese Minister of Foreign Affairs Wang Yi (王毅) gave a subtle message to tone down public criticism of growing Chinese assertiveness in the disputed South China Sea.
The diplomat said Wang did not ask for anything in exchange for vaccines, but it was clear he wanted “friendly exchanges in public, like control your megaphone diplomacy a little.”
The diplomat spoke on condition of anonymity to discuss the issue publicly.
Still, the pandemic’s urgency has largely superseded hesitations over China’s vaccines.
“Vaccines, particularly those made in the West, are reserved for rich countries,” said one Egyptian official, who spoke on condition of anonymity to discuss the matter. “We had to guarantee a vaccine. Any vaccine.”
BEIJING BAILOUT: Pyongyang’s economic woes would not lead to famine because China will not let that happen due to its fear of a pro-US unified Korea, experts say North Korean leader Kim Jong-un has called for another “arduous march” to fight severe economic difficulties, for the first time comparing them to a 1990s famine that killed hundreds of thousands. Kim had previously said his nation faces its “worst-ever” situation due to several factors — including the COVID-19 pandemic, US-led sanctions and natural disasters in the summer last year — but it is the first time he has publicly drawn a parallel with the deadly famine. North Korea monitoring groups have not detected any signs of mass starvation or a humanitarian disaster, but Kim’s comments still suggest how seriously he views
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
A years-long David and Goliath fight which has seen two Australian surfers take on a Chinese-linked company over alleged damage of an idyllic Fijian island has come to its conclusion after a court handed down a guilty verdict against the developers yesterday. The case has been described by Pacific legal experts as a “watershed” moment that tested Fijian environmental laws, as well as the willingness of the nation — which presents itself as a global climate leader — to “walk the walk” on environmental issues. Freesoul, a Chinese-linked company, in 2018 began work on Malolo Island, with plans to build Fiji’s largest